Ocera Therapeutics to Present at BIO Investor on October 8, 2013

Ocera logo

SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, will present at the 12th Annual BIO Investor Forum taking place at the Palace Hotel in San Francisco, CA October 8-9, 2013. Ocera's presentation is scheduled for Tuesday at 04:00 PM PT in the Sea Cliff Presentation Room.

A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com.

About Ocera Therapeutics

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera's lead drug candidate OCR-002 (ornithine phenylacetate), which has been granted Orphan Disease and Fast Track status from FDA, is an ammonia scavenger in clinical development to treat hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. For additional information, please see www.ocerainc.com.

CONTACT: Inquiries Susan Sharpe Director, Corporate Communications Ocera Therapeutics, Inc. (919) 328-1109 ssharpe@ocerainc.com

Source:Ocera Therapeutics, Inc.